This paper explores recent episodes in the field of biotechnology research as regards intellectual property rights. It argues that public research institutes develop schizophrenic intellectual property policies. On the one hand, they are aimed at combating poverty through the development of freely accessible knowledge and biotechnologies, but, on the other hand, they perform a policy in which patents are regarded as a crucial tool for acquiring research contracts, safeguard a top position in research rankings and to boost income.